Company analysis

Emerging Pharma
Big Pharma
Mid Pharma
Japan Pharma
Hot Topics
M&A Analysis

Sort by Price

Click to order products ascending

Display 30 Products per page

Company Analysis: Novartis

$3,000.00

PharmaVitae explores Novartis’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.
January 25, 2021
Find out more
Company Analysis: Novo Nordisk

$3,000.00

PharmaVitae explores Novo Nordisk’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.
January 25, 2021
Find out more
Company Analysis: Pfizer

$3,000.00

PharmaVitae explores Pfizer’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.
August 28, 2020
Find out more
Company Analysis: Roche

$3,000.00

PharmaVitae explores Roche’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.
January 25, 2021
Find out more
Company Analysis: Sanofi

$3,000.00

PharmaVitae explores Sanofi’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts.
January 25, 2021
Find out more
Company Analysis: Teva

$3,000.00

PharmaVitae explores Teva’s prescription pharmaceutical performance and outlook over 2019–29.
January 25, 2021
Find out more
Japan Pharma Outlook

$3,000.00

Datamonitor’s Japan Pharma peer set contains the top 10 companies headquartered in Japan: Takeda Pharmaceuticals, Astellas Pharma, Daiichi Sankyo, Otsuka Pharmaceutical, Eisai, Mitsubishi Tanabe Pharma, Chugai Pharmaceutical, Dainippon Sumitomo, Shionogi & Co and Kyowa Hakko Kirin.
September 28, 2016
Find out more
Company Analysis: Astellas

$3,000.00

PharmaVitae explores Astellas’s prescription pharmaceutical performance and outlook over 2019–29.
January 28, 2021
Find out more
Company Analysis: Daiichi Sankyo

$3,000.00

PharmaVitae explores Daiichi Sankyo’s prescription pharmaceutical performance and outlook over 2019–29.
January 28, 2021
Find out more
Company Analysis: Sumitomo Dainippon

$3,000.00

PharmaVitae explores Sumitomo Dainippon’s prescription pharmaceutical performance and outlook over 2019–29.
January 28, 2021
Find out more
Company Analysis: Eisai

$3,000.00

PharmaVitae explores Eisai’s prescription pharmaceutical performance and outlook over 2019–29.
January 28, 2021
Find out more
Actelion

$3,000.00

Analysis of Actelion’s prescription pharmaceutical sales encompassing global corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2015–25.
November 1, 2016
Find out more
Company Analysis: Otsuka

$3,000.00

PharmaVitae explores Otsuka’s prescription pharmaceutical performance and outlook over 2019–29.
January 29, 2020
Find out more
Company Analysis: Takeda

$3,000.00

PharmaVitae explores Takeda’s prescription pharmaceutical performance and outlook over 2019–29.
January 29, 2021
Find out more
2016 M&A Analysis

$3,000.00

Datamonitor Healthcare’s PharmaVitae team explores the value in the flurry of recent deals, shedding light on incentives and how

they may influence the market and future deal-making.
September 7, 2016
Find out more
Company Analysis: Shionogi

$3,000.00

PharmaVitae explores Shionogi’s prescription pharmaceutical performance and outlook through to 2029.
January 29, 2021
Find out more
Shire Company Analysis

$3,000.00

PharmaVitae explores Shire’s prescription pharmaceutical performance and outlook over 2017–27. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts
August 30, 2018
Find out more
Company Analysis: Johnson & Johnson

$3,000.00

PharmaVitae explores Johnson & Johnson’s prescription pharmaceutical performance and outlook over 2019–29.
January 25, 2021
Find out more
Company Analysis: Incyte

$3,000.00

PharmaVitae explores Incyte’s prescription pharmaceutical performance and outlook over 2019–29.
January 25, 2021
Find out more
JP Morgan Healthcare Conference Preview

$3,000.00

PharmaVitae previews companies presenting at the JP Morgan Healthcare Conference to be held in San Francisco over 8–11 January 2018.
January 10, 2018
Find out more
JP Morgan Healthcare Conference Review

$3,000.00

The 2018 JP Morgan Healthcare Conference held in San Francisco over 8–11 January 2018 was light on big news and deals, but PharmaVitae picked up on key themes for some of the presenting companies in our coverage universe, which are all experiencing and/or pursuing a change of scene and pace in dealmaking activity.
January 18, 2018
Find out more
Company Analysis: BioMarin

$3,000.00

PharmaVitae explores BioMarin’s prescription pharmaceutical performance and outlook over 2019–29.
January 25, 2021
Find out more
Acorda Company Analysis

$3,000.00

PharmaVitae explores Acorda’s prescription pharmaceutical performance and outlook over 2017–27.
February 9, 2018
Find out more
M&A Outlook 2018

$3,000.00

PharmaVitae explores the rationale for accelerated dealmaking in 2018, earmarking companies touted for M&A activity, and details 27 targets that potential acquirers should prioritize based on strategic themes, KOL interviews, and physician surveys.
April 24, 2018
Find out more
Japan Pharma Outlook 2027

$3,000.00

PharmaVitae explores and visualizes market dynamics in the Japan Pharma peer set out to 2027* through analysis and in-house sales forecasts for more than 320 products.
July 2, 2018
Find out more
M&A Analysis 2018

$3,000.00

PharmaVitae has launched the M&A Outlook 2018 report, click to view the 27 targets that potential acquirers should prioritize based on strategic themes, KOL interviews, and physician surveys.
April 24, 2018
Find out more
Under the Radar Takeover Targets

$3,000.00

Following on from its M&A Outlook 2018 report, PharmaVitae highlights under the radar takeover targets that are potentially attractive to companies on the prowl for acquisitions.
July 20, 2018
Find out more
Company Analysis: Vertex

$3,000.00

PharmaVitae explores Vertex’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts.
January 25, 2021
Find out more
The Latest in Immuno-Oncology: A Deep Dive into Non-Small Cell Lung Cancer (NSCLC)

$3,000.00

This decade has seen the emergence of therapies harnessing the immune system to treat cancer.
October 1, 2018
Find out more
Company Analysis: GlaxoSmithKline

$3,000.00

PharmaVitae explores GlaxoSmithKline’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.
January 25, 2021
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726

Call Back

Name

Email *

Company name *

Phone number *